JP2019530449A - 幹細胞様メモリーt細胞の生成および養子免疫療法における使用 - Google Patents
幹細胞様メモリーt細胞の生成および養子免疫療法における使用 Download PDFInfo
- Publication number
- JP2019530449A JP2019530449A JP2019515991A JP2019515991A JP2019530449A JP 2019530449 A JP2019530449 A JP 2019530449A JP 2019515991 A JP2019515991 A JP 2019515991A JP 2019515991 A JP2019515991 A JP 2019515991A JP 2019530449 A JP2019530449 A JP 2019530449A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- antigen
- specific
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000003071 memory t lymphocyte Anatomy 0.000 title claims abstract description 47
- 238000009169 immunotherapy Methods 0.000 title description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 951
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 860
- 239000000427 antigen Substances 0.000 claims abstract description 557
- 108091007433 antigens Proteins 0.000 claims abstract description 557
- 102000036639 antigens Human genes 0.000 claims abstract description 557
- 238000000034 method Methods 0.000 claims abstract description 258
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 91
- 201000011510 cancer Diseases 0.000 claims abstract description 85
- 244000052769 pathogen Species 0.000 claims abstract description 78
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 75
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 31
- 210000000601 blood cell Anatomy 0.000 claims description 174
- 108091008874 T cell receptors Proteins 0.000 claims description 124
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 114
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 85
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 85
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 83
- 102100033467 L-selectin Human genes 0.000 claims description 83
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 70
- 206010070834 Sensitisation Diseases 0.000 claims description 69
- 230000008313 sensitization Effects 0.000 claims description 69
- 241000701022 Cytomegalovirus Species 0.000 claims description 59
- 238000000338 in vitro Methods 0.000 claims description 55
- 108700028369 Alleles Proteins 0.000 claims description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 53
- 150000007523 nucleic acids Chemical class 0.000 claims description 49
- 108020004707 nucleic acids Proteins 0.000 claims description 48
- 102000039446 nucleic acids Human genes 0.000 claims description 48
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 47
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 47
- 108091008048 CMVpp65 Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 34
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 31
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 31
- 230000002463 transducing effect Effects 0.000 claims description 29
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 210000005260 human cell Anatomy 0.000 claims description 23
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 19
- 230000002163 immunogen Effects 0.000 claims description 16
- 230000003013 cytotoxicity Effects 0.000 claims description 15
- 231100000135 cytotoxicity Toxicity 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 230000000735 allogeneic effect Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 238000010257 thawing Methods 0.000 claims description 14
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 9
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 8
- 208000008383 Wilms tumor Diseases 0.000 claims description 8
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 8
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 8
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 8
- 210000004443 dendritic cell Anatomy 0.000 claims description 8
- 208000024908 graft versus host disease Diseases 0.000 claims description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 6
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 6
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 6
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 4
- 241001115402 Ebolavirus Species 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 230000030741 antigen processing and presentation Effects 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000001219 parotid gland cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000004091 Parotid Neoplasms Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 112
- 230000000638 stimulation Effects 0.000 description 111
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 69
- 210000004369 blood Anatomy 0.000 description 66
- 239000008280 blood Substances 0.000 description 66
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 56
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 56
- 102100027207 CD27 antigen Human genes 0.000 description 40
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 40
- 230000015654 memory Effects 0.000 description 35
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 32
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 27
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 27
- 230000001965 increasing effect Effects 0.000 description 25
- 230000000779 depleting effect Effects 0.000 description 24
- 230000004044 response Effects 0.000 description 23
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 21
- 230000001235 sensitizing effect Effects 0.000 description 20
- 230000035755 proliferation Effects 0.000 description 19
- 230000002062 proliferating effect Effects 0.000 description 18
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 102100037850 Interferon gamma Human genes 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 14
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 14
- 230000003834 intracellular effect Effects 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 230000000139 costimulatory effect Effects 0.000 description 13
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 239000011886 peripheral blood Substances 0.000 description 12
- 238000005138 cryopreservation Methods 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102000003812 Interleukin-15 Human genes 0.000 description 10
- 108090000172 Interleukin-15 Proteins 0.000 description 10
- 108010002586 Interleukin-7 Proteins 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- 230000009258 tissue cross reactivity Effects 0.000 description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000007503 antigenic stimulation Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000007710 freezing Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- -1 CD127 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000002458 cell surface marker Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000979735 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102100024975 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Human genes 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000007481 next generation sequencing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000002338 cryopreservative effect Effects 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000009758 senescence Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000829111 Human polyomavirus 1 Species 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 230000033540 T cell apoptotic process Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 108010021994 cytomegalovirus matrix protein 65kDa Proteins 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000002998 immunogenetic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000010212 intracellular staining Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 101150059079 EBNA1 gene Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- 241000701027 Human herpesvirus 6 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 101150113776 LMP1 gene Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000579048 Merkel cell polyomavirus Species 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000004940 costimulation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010048983 Cytomegalovirus colitis Diseases 0.000 description 1
- 206010058854 Cytomegalovirus viraemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 101150113929 EBNA2 gene Proteins 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101900065606 Human cytomegalovirus Immediate early protein IE1 Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102000015223 NK Cell Lectin-Like Receptors Human genes 0.000 description 1
- 108010039435 NK Cell Lectin-Like Receptors Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 208000020023 cytomegalovirus pneumonia Diseases 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000007419 viral reactivation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
Abstract
Description
本願は、2016年9月23日に出願された米国仮出願第62/399,311号の利益を主張し、その全体が、参照によって本明細書中に組み込まれる。
本発明は、国立衛生研究所によって授与されたCA023766のもとの政府援助により行われた。政府は、本発明において一定の権利を有する。
電子的に提出された配列表の参照
本明細書における参考文献の引用は、それが本開示の先行技術であると容認するものと解釈されるべきではない。
5.1.養子免疫療法用の抗原特異的T細胞を生成する方法
5.1.1.TSCM細胞のex vivo感作を使用する方法
5.1.2.TCRが形質導入されたTSCM細胞を使用する方法
5.1.3.CARが形質導入されたTSCM細胞を使用する方法
5.1.4.ヒト血液細胞の集団
5.2.生成された抗原特異的T細胞を使用して患者を処置する方法
5.2.1.投与および投与量
5.2.2.異なる細胞集団を用いた段階的処置
5.2.3.追加的な治療
5.3.抗原特異的T細胞を含む細胞の集団およびそれらの特徴付け
5.3.1.細胞傷害性
5.3.2.同種異系反応性
5.3.3.HLA型
5.3.4.組成物およびキット
5.4.抗原特異性および患者
6.1.概要
6.2.材料および方法
6.2.1.ドナー
6.2.2.CMV特異的T細胞の生成
6.2.3.四量体分析による抗原特異的CD8+T細胞の定量化
6.2.4.T細胞サブセットの表現型解析
6.2.5.抗原特異的T細胞の機能的特徴付け
6.2.6.T細胞増殖およびアポトーシスの分析
6.2.7.TCR次世代配列決定
6.2.8.統計解析
6.3.結果
6.3.1.健康な血清陽性ドナー由来のPBMC内のCMV pp65特異的TSCM細胞の検出および単離
6.3.2.エピトープ特異的TSCM細胞をin vitroにおいて首尾よく増大させ、抗原特異的刺激中に分化の程度が低いメモリー表現型を維持することができる
6.3.3.メモリーT細胞集団内の共刺激マーカーおよび老化マーカーの特徴付け
6.3.4.TSCM由来T細胞では優れた抗原特異的T細胞の増大を導く高い増殖能力が実証される
6.3.5.in vitroで増大させたTN由来T細胞およびTSCM由来T細胞では、TCM由来T細胞およびTEM由来T細胞と同様に特異的なエピトープに対する機能活性が実証される
6.3.6.in vitroで増大させたTSCM由来のCMV特異的T細胞は、TCM由来集団およびTEM由来集団のものと同様のパブリックTCRのオリゴクローナルレパートリーを示す
6.4.考察
7.参照による組み込み
Claims (80)
- 病原体またはがんを有するかまたはその疑いがあるヒト患者への治療的投与のための抗原特異的T細胞を含む細胞の集団を生成する方法であって、(a)ヒト血液細胞の集団を、前記病原体またはがんの1つまたは複数の抗原に培養下で所定期間にわたりex vivo感作させるステップであって、前記期間の開始時に前記ヒト血液細胞の集団が少なくとも50%の幹細胞様メモリーT細胞(TSCM細胞)を含有する、ステップと、(b)(i)前記ex vivo感作させたヒト血液細胞の集団、または(ii)それに由来する、前記病原体もしくはがんの1つもしくは複数の抗原を認識する抗原特異的T細胞を含む細胞を凍結保存するステップとを含み、それにより、前記抗原特異的T細胞を含む細胞の集団を産生する方法。
- 凍結保存するステップの後に、前記ex vivo感作させたヒト血液細胞またはそれに由来する細胞の集団を解凍するステップ、および必要に応じて、培養下で増大させるステップをさらに含む、請求項1に記載の方法。
- 前記培養下におく期間が、9〜21日間の範囲である、請求項1または2に記載の方法。
- 前記培養下におく期間が、9〜14日間の範囲である、請求項3に記載の方法。
- 前記培養下におく期間が、14日間である、請求項3に記載の方法。
- 前記ex vivo感作ステップが、前記ヒト血液細胞の集団を、前記1つまたは複数の抗原に由来する1つまたは複数の免疫原性ペプチドまたはタンパク質と共培養することを含む、請求項1から5までのいずれかに記載の方法。
- 前記ex vivo感作ステップが、前記ヒト血液細胞の集団を、前記1つまたは複数の抗原を提示する抗原提示細胞と共培養することを含む、請求項1から5までのいずれかに記載の方法。
- 前記抗原提示細胞が、樹状細胞、サイトカインにより活性化された単球、末梢血単核細胞(PBMC)、エプスタイン・バーウイルスにより形質転換されたBリンパ芽球様細胞株細胞(EBV−BLCL細胞)、または人工抗原提示細胞(AAPC)である、請求項7に記載の方法。
- 前記抗原提示細胞がAAPCである、請求項8に記載の方法。
- 前記抗原提示細胞が、前記1つまたは複数の抗原に由来する1つまたは複数の免疫原性ペプチドまたはタンパク質が負荷されたものである、請求項7から9までのいずれかに記載の方法。
- 前記抗原提示細胞が、前記1つまたは複数の抗原に由来する1つまたは複数の免疫原性ペプチドまたはタンパク質を組換え発現するように遺伝子操作されたものである、請求項7から9までのいずれかに記載の方法。
- 前記1つまたは複数の免疫原性ペプチドまたはタンパク質が、前記1つまたは複数の抗原に由来するオーバーラップするペプチドのプールである、請求項6、10および11のいずれかに記載の方法。
- 前記オーバーラップするペプチドのプールが、オーバーラップするペンタデカペプチドのプールである、請求項12に記載の方法。
- 前記1つまたは複数の免疫原性ペプチドまたはタンパク質が、前記1つまたは複数の抗原に由来する1つまたは複数のタンパク質である、請求項6、10および11のいずれかに記載の方法。
- 前記抗原特異的T細胞を含む細胞の集団が、前記1つまたは複数の抗原を認識するパブリックT細胞受容体(TCR)を内因的に発現する抗原特異的T細胞を含む、請求項1から14までのいずれかに記載の方法。
- 前記抗原特異的T細胞を含む細胞の集団が、前記1つまたは複数の抗原を認識するパブリックTCRを組換え発現する抗原特異的T細胞を含む、請求項1から14までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団にパブリックTCRをコードする核酸を形質導入するステップをさらに含む、請求項16に記載の方法。
- 前記形質導入するステップが、前記ヒト血液細胞の集団を3〜5日間培養した時点で、前記ヒト血液細胞の集団に前記パブリックTCRをコードする前記核酸を形質導入することを含む、請求項17に記載の方法。
- 前記1つまたは複数の抗原がサイトメガロウイルス(CMV)pp65であり、前記パブリックTCRが配列番号3の相補性決定領域(CDR)3を含む可変ドメインを含むβ鎖を含む、請求項15から18までのいずれかに記載の方法。
- 前記1つまたは複数の抗原がCMV pp65であり、前記パブリックTCRが配列番号4のCDR3を含む可変ドメインを含むβ鎖を含む、請求項15から18までのいずれかに記載の方法。
- 前記抗原特異的T細胞を含む細胞の集団が、前記1つまたは複数の抗原を認識するキメラ抗原受容体(CAR)を組換え発現する抗原特異的T細胞を含む、請求項1から14までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団にCARをコードする核酸を形質導入するステップをさらに含む、請求項21に記載の方法。
- 前記ヒト血液細胞の集団を3〜5日間培養した時点で、前記ヒト血液細胞の集団に前記CARをコードする前記核酸を形質導入するステップをさらに含む、請求項22に記載の方法。
- 病原体またはがんを有するかまたはその疑いがあるヒト患者への治療的投与のための抗原特異的T細胞を含む細胞の集団を生成する方法であって、ヒト血液細胞の集団を3〜5日間培養した時点で、前記ヒト血液細胞の集団に前記病原体またはがんの1つまたは複数の抗原を認識するパブリックTCRをコードする核酸を形質導入するステップであって、前記ヒト血液細胞の集団が、少なくとも50%のTSCM細胞を含有する、ステップを含み、それにより、前記抗原特異的T細胞を含む細胞の集団を産生する方法。
- 前記1つまたは複数の抗原がCMV pp65であり、前記パブリックTCRが配列番号3のCDR3を含む可変ドメインを含むβ鎖を含む、請求項24に記載の方法。
- 前記1つまたは複数の抗原がCMV pp65であり、前記パブリックTCRが配列番号4のCDR3を含む可変ドメインを含むβ鎖を含む、請求項24に記載の方法。
- CMV感染症を有するかまたはその疑いがあるヒト患者への治療的投与のための抗原特異的T細胞を含む細胞の集団を生成する方法であって、ヒト血液細胞の集団に、CMV pp65を認識するパブリックTCRをコードする核酸を形質導入するステップであって、前記パブリックTCRが配列番号3のCDR3を含む可変ドメインを含むβ鎖を含み、前記ヒト血液細胞の集団が少なくとも50%のTSCM細胞を含有する、ステップを含み、それにより、前記抗原特異的T細胞を含む細胞の集団を産生する方法。
- CMV感染症を有するかまたはその疑いがあるヒト患者への治療的投与のための抗原特異的T細胞を含む細胞の集団を生成する方法であって、ヒト血液細胞の集団に、CMV pp65を認識するパブリックTCRをコードする核酸を形質導入するステップであって、前記パブリックTCRが配列番号4のCDR3を含む可変ドメインを含むβ鎖を含み、前記ヒト血液細胞の集団が少なくとも50%のTSCM細胞を含有する、ステップを含み、それにより、前記抗原特異的T細胞を含む細胞の集団を産生する方法。
- 病原体またはがんを有するかまたはその疑いがあるヒト患者への治療的投与のための抗原特異的T細胞を含む細胞の集団を生成する方法であって、ヒト血液細胞の集団を3〜5日間培養した時点で前記ヒト血液細胞の集団に前記病原体またはがんの1つまたは複数の抗原を認識するCARをコードする核酸を形質導入するステップであって、前記ヒト血液細胞の集団が、少なくとも50%のTSCM細胞を含有する、ステップを含み、それにより、前記抗原特異的T細胞を含む細胞の集団を産生する方法。
- 前記形質導入するステップの後に、前記形質導入されたヒト血液細胞またはそれに由来する細胞の集団を凍結保存するステップをさらに含む、請求項24から29までのいずれかに記載の方法。
- 前記凍結保存するステップの後に、前記形質導入されたヒト血液細胞またはそれに由来する細胞の集団を解凍し、必要に応じて培養下で増大させるステップをさらに含む、請求項30に記載の方法。
- 前記ヒト血液細胞の集団が、少なくとも90%のTSCM細胞を含有する、請求項1から31までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団が、少なくとも95%のTSCM細胞を含有する、請求項1から31までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団が、少なくとも99%のTSCM細胞を含有する、請求項1から31までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団が、100%のTSCM細胞を含有する、請求項1から31までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団が、10%未満のナイーブT(TN)細胞を含有する、請求項1から35までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団が、5%未満のTN細胞を含有する、請求項1から35までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団が、1%未満のTN細胞を含有する、請求項1から35までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団が、TN細胞を含有しない、請求項1から35までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団をヒト細胞試料から引き出すステップをさらに含む、請求項1から39までのいずれかに記載の方法。
- 前記引き出すステップが、前記ヒト細胞試料からTSCM細胞を濃縮することを含む、請求項40に記載の方法。
- 前記濃縮するステップが、CD3+CD62L+CD45RO−CD95+である細胞を選択することを含む、請求項41に記載の方法。
- 前記引き出すステップが、蛍光活性化細胞選別(FACS)によって前記ヒト細胞試料からTSCM細胞を選別することを含む、請求項40から42までのいずれかに記載の方法。
- 前記ヒト血液細胞の集団が、前記1つまたは複数の抗原について血清陽性であるヒトドナーに由来するものである、請求項1から43までのいずれかに記載の方法。
- 前記抗原特異的T細胞を含む細胞の集団が、前記1つまたは複数の抗原に由来する1つまたは複数のペプチドまたはタンパク質が負荷されていないまたはそれを発現するように遺伝子操作されていない抗原提示細胞に対するin vitroにおける実質的な細胞傷害性を欠く、請求項1から44までのいずれかに記載の方法。
- 前記ex vivo感作ステップが、前記ヒト血液細胞の集団を、前記病原体の1つまたは複数の抗原にex vivo感作させることを含む、請求項1から45までのいずれかに記載の方法。
- 前記病原体が、ウイルス、細菌、真菌、蠕虫または原生生物である、請求項46に記載の方法。
- 前記病原体がウイルスである、請求項46に記載の方法。
- 前記ウイルスがCMVである、請求項48に記載の方法。
- 前記ex vivo感作ステップが、前記ヒト血液細胞の集団を、エプスタイン・バーウイルス(EBV)の1つまたは複数の抗原にex vivo感作させることを含む、請求項1から18まで、21から24まで、および29から45までのいずれかに記載の方法。
- 前記ex vivo感作ステップが、前記ヒト血液細胞の集団を、BKV、JCV、ヘルペスウイルス、アデノウイルス、ヒト免疫不全ウイルス、インフルエンザウイルス、エボラウイルス、ポックスウイルス、ラブドウイルス、またはパラミクソウイルスの1つまたは複数の抗原にex vivo感作させることを含む、請求項1から18まで、21から24まで、および29から45までのいずれかに記載の方法。
- 前記ex vivo感作ステップが、前記ヒト血液細胞の集団を、前記がんの1つまたは複数の抗原にex vivo感作させることを含む、請求項1から18まで、21から24まで、および29から45までのいずれか一項に記載の方法。
- 前記がんが、血液がんである、請求項52に記載の方法。
- 前記がんが、多発性骨髄腫または形質細胞白血病である、請求項53に記載の方法。
- 前記がんの前記1つまたは複数の抗原が、ウィルムス腫瘍1(WT1)である、請求項54に記載の方法。
- 前記がんが、乳がん、肺がん、卵巣がん、胃がん、膵臓がん、喉頭がん、食道がん、精巣がん、肝臓がん、耳下腺がん、胆道がん、結腸がん、直腸がん、子宮頸がん、子宮がん、子宮内膜がん、腎臓がん、膀胱がん、前立腺がん、甲状腺がん、脳がん、または皮膚がんである、請求項52に記載の方法。
- 病原体またはがんを有するヒト患者を処置する方法であって、(i)請求項1から56までのいずれかに記載の方法に従って抗原特異的T細胞を含む細胞の集団を生成するステップと、(ii)前記抗原特異的T細胞を含む細胞の集団を前記ヒト患者に投与するステップとを含む方法。
- 病原体またはがんを有するヒト患者を処置する方法であって、抗原特異的T細胞を含む細胞の集団を前記ヒト患者に投与するステップであって、前記抗原特異的T細胞を含む細胞の集団が、請求項1から56までのいずれかに記載の方法に従って抗原特異的T細胞を含む細胞の集団を生成することを含む方法の産生物である、ステップを含む方法。
- 前記抗原特異的T細胞を含む細胞の集団に含有される前記抗原特異的T細胞が、前記ヒト患者の疾患細胞と共有するHLA対立遺伝子によって拘束される、請求項57または58に記載の方法。
- 前記抗原特異的T細胞を含む細胞の集団に含有される前記抗原特異的T細胞が、前記ヒト患者の前記疾患細胞と8つのHLA対立遺伝子のうち少なくとも2つを共有する、請求項57から59までのいずれかに記載の方法。
- 前記8つのHLA対立遺伝子が、2つのHLA−A対立遺伝子、2つのHLA−B対立遺伝子、2つのHLA−C対立遺伝子、および2つのHLA−DR対立遺伝子である、請求項60に記載の方法。
- 前記ヒト血液細胞の集団が、前記ヒト患者に対して同種異系であるヒトドナーに由来するものである、請求項57から61までのいずれかに記載の方法。
- 前記ヒト患者が、移植ドナーからの移植のレシピエントであり、前記ヒトドナーが、移植ドナーとは異なる第三者ドナーである、請求項62に記載の方法。
- 前記投与するステップが、前記抗原特異的T細胞を含む細胞の集団を、前記ヒト患者に前記ヒト患者1kg当たり前記抗原特異的T細胞を含む細胞の集団の細胞約1×105個未満またはそれと等しい用量で投与することを含む、請求項57から63までのいずれかに記載の方法。
- 前記投与するステップが、前記抗原特異的T細胞を含む細胞の集団を前記ヒト患者に前記ヒト患者1kg当たり前記抗原特異的T細胞を含む細胞の集団の細胞約5×104個未満またはそれと等しい用量で投与することを含む、請求項57から63までのいずれかに記載の方法。
- 前記投与するステップが、前記抗原特異的T細胞を含む細胞の集団を前記ヒト患者に前記ヒト患者1kg当たり前記抗原特異的T細胞を含む細胞の集団の細胞約1×104個未満またはそれと等しい用量で投与することを含む、請求項57から63までのいずれかに記載の方法。
- 前記投与するステップが、前記抗原特異的T細胞を含む細胞の集団を前記ヒト患者に前記ヒト患者1kg当たり前記抗原特異的T細胞を含む細胞の集団の細胞約5×103個未満またはそれと等しい用量で投与することを含む、請求項57から63までのいずれかに記載の方法。
- 前記投与するステップが、前記抗原特異的T細胞を含む細胞の集団を前記ヒト患者に前記ヒト患者1kg当たり前記抗原特異的T細胞を含む細胞の集団の細胞約1×103個未満またはそれと等しい用量で投与することを含む、請求項57から63までのいずれかに記載の方法。
- 前記投与するステップが、前記抗原特異的T細胞を含む細胞の集団を前記ヒト患者に前記用量で毎週投与することを含む、請求項57から68までのいずれかに記載の方法。
- 前記投与するステップが、ボーラス静脈内注入によるものである、請求項57から69までのいずれかに記載の方法。
- 前記投与するステップが、少なくとも2用量の、前記抗原特異的T細胞を含む細胞の集団を前記ヒト患者に投与することを含む、請求項57から70までのいずれかに記載の方法。
- 前記投与するステップが、2用量、3用量、4用量、5用量、または6用量の、前記抗原特異的T細胞を含む細胞の集団を前記ヒト患者に投与することを含む、請求項57から70までのいずれかに記載の方法。
- 前記投与するステップが、前記抗原特異的T細胞を含む細胞の集団を、3週間連続して1週間当たり1用量の第1のサイクル、その後、前記抗原特異的T細胞を含む細胞の集団の用量を投与しない休薬期間、その後、前記抗原特異的T細胞を含む細胞の集団を、3週間連続して1週間当たり前記1用量の第2のサイクルを投与することを含む、請求項57から70までのいずれかに記載の方法。
- 前記投与するステップが、前記抗原特異的T細胞を含む細胞の集団を、3週間連続して1週間当たり1用量のサイクルを2回、3回、4回、5回、または6回投与することを含み、各サイクルが、前記抗原特異的T細胞を含む細胞の集団の用量を投与しない休薬期間によって隔てられる、請求項57から70までのいずれかに記載の方法。
- 前記休薬期間が、約1週間、約2週間、約3週間、または約4週間である、請求項73または74に記載の方法。
- 前記休薬期間が、約3週間である、請求項73または74に記載の方法。
- 前記抗原特異的T細胞を含む細胞の集団を投与するステップにより前記ヒト患者においていかなる移植片対宿主病(GvHD)も生じない、請求項57から76までに記載の方法。
- 病原体またはがんを有するかまたはその疑いがあるヒト患者への治療的投与のための抗原特異的T細胞を含む細胞の集団であって、請求項1から56までのいずれかに記載の方法に従って抗原特異的T細胞を含む細胞の集団を生成することを含む方法の産生物である、集団。
- 病原体またはがんを有するかまたはその疑いがあるヒト患者への治療的投与のための抗原特異的T細胞を含む細胞の集団であって、請求項1、請求項3から30まで、および請求項32から56までのいずれかに記載の方法に従って抗原特異的T細胞を含む細胞の集団を生成することを含む方法の産生物であり、凍結保存されている、集団。
- 請求項78または79に記載の複数の集団を含む細胞バンク。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022068256A JP2022087340A (ja) | 2016-09-23 | 2022-04-18 | 幹細胞様メモリーt細胞の生成および養子免疫療法における使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662399311P | 2016-09-23 | 2016-09-23 | |
US62/399,311 | 2016-09-23 | ||
PCT/US2017/052846 WO2018057823A1 (en) | 2016-09-23 | 2017-09-22 | Generation and use in adoptive immunotherapy of stem cell-like memory t cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022068256A Division JP2022087340A (ja) | 2016-09-23 | 2022-04-18 | 幹細胞様メモリーt細胞の生成および養子免疫療法における使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019530449A true JP2019530449A (ja) | 2019-10-24 |
JP2019530449A5 JP2019530449A5 (ja) | 2020-11-12 |
Family
ID=60117744
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019515991A Ceased JP2019530449A (ja) | 2016-09-23 | 2017-09-22 | 幹細胞様メモリーt細胞の生成および養子免疫療法における使用 |
JP2022068256A Pending JP2022087340A (ja) | 2016-09-23 | 2022-04-18 | 幹細胞様メモリーt細胞の生成および養子免疫療法における使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022068256A Pending JP2022087340A (ja) | 2016-09-23 | 2022-04-18 | 幹細胞様メモリーt細胞の生成および養子免疫療法における使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10857182B2 (ja) |
EP (1) | EP3515461A1 (ja) |
JP (2) | JP2019530449A (ja) |
AR (1) | AR109707A1 (ja) |
AU (1) | AU2017330379B2 (ja) |
CA (1) | CA3037002A1 (ja) |
WO (1) | WO2018057823A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021085398A1 (ja) * | 2019-10-28 | 2021-05-06 | 第一三共株式会社 | Cd45ra+およびccr7+の細胞表面マーカーを有するt細胞の製造方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013188427A1 (en) * | 2012-06-11 | 2013-12-19 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
EP3515461A1 (en) | 2016-09-23 | 2019-07-31 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory t cells |
US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
AU2019268545A1 (en) * | 2018-05-18 | 2020-12-10 | The Council Of The Queensland Institute Of Medical Research | Adoptive T-cell therapy for CMV infection and CMV-associated diseases |
KR20220104217A (ko) | 2019-11-26 | 2022-07-26 | 노파르티스 아게 | Cd19 및 cd22 키메라 항원 수용체 및 이의 용도 |
WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
CN113512529B (zh) * | 2021-07-21 | 2022-11-25 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ab的制备方法 |
CN114578048B (zh) * | 2021-12-22 | 2023-08-08 | 重庆医科大学附属儿童医院 | 一种t淋巴细胞发育亚群免疫分型的方法和试剂盒 |
WO2023142683A1 (zh) * | 2022-01-27 | 2023-08-03 | 上海市第一人民医院 | 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3753357A (en) | 1970-12-14 | 1973-08-21 | Ovitron Res Corp | Method and apparatus for the preservation of cells and tissues |
US4199022A (en) | 1978-12-08 | 1980-04-22 | The United States Of America As Represented By The Department Of Energy | Method of freezing living cells and tissues with improved subsequent survival |
US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
US7163685B2 (en) | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
EP4218806A1 (en) | 2008-06-20 | 2023-08-02 | Duke University | Compositions and kits for eliciting an immune response |
AU2011295845B2 (en) | 2010-09-01 | 2016-09-22 | Baylor College Of Medicine | EBV-specific cytotoxic T-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (NPC) |
WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
AU2015218865B2 (en) * | 2014-02-21 | 2021-06-10 | Coimmune, Inc. | TSCM cells and methods for use |
PE20171135A1 (es) | 2014-11-05 | 2017-08-09 | Memorial Sloan Kettering Cancer Center | Metodos para seleccionar una linea de celulas t y donador de la misma para terapia celular adoptiva |
AU2016344745A1 (en) * | 2015-10-28 | 2018-05-17 | Life Technologies As | Selective expansion of different subpopulations of T cells by the alteration of cell surfacing signals and signal ratio |
EP3515461A1 (en) | 2016-09-23 | 2019-07-31 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory t cells |
-
2017
- 2017-09-22 EP EP17784722.5A patent/EP3515461A1/en active Pending
- 2017-09-22 US US16/333,651 patent/US10857182B2/en active Active
- 2017-09-22 WO PCT/US2017/052846 patent/WO2018057823A1/en active Application Filing
- 2017-09-22 CA CA3037002A patent/CA3037002A1/en active Pending
- 2017-09-22 AU AU2017330379A patent/AU2017330379B2/en active Active
- 2017-09-22 AR ARP170102632A patent/AR109707A1/es unknown
- 2017-09-22 JP JP2019515991A patent/JP2019530449A/ja not_active Ceased
-
2022
- 2022-04-18 JP JP2022068256A patent/JP2022087340A/ja active Pending
Non-Patent Citations (2)
Title |
---|
BONE MARROW TRANSPLANTATION, vol. 51, JPN6021034560, 2016, pages 1163 - 1172, ISSN: 0004800281 * |
THE JOURNAL OF IMMUNOLOGY, vol. 194, JPN6021034561, 2015, pages 5559 - 5567, ISSN: 0004800280 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021085398A1 (ja) * | 2019-10-28 | 2021-05-06 | 第一三共株式会社 | Cd45ra+およびccr7+の細胞表面マーカーを有するt細胞の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2022087340A (ja) | 2022-06-09 |
WO2018057823A1 (en) | 2018-03-29 |
US20200009189A1 (en) | 2020-01-09 |
EP3515461A1 (en) | 2019-07-31 |
US10857182B2 (en) | 2020-12-08 |
AR109707A1 (es) | 2019-01-16 |
AU2017330379B2 (en) | 2023-07-13 |
AU2017330379A1 (en) | 2019-04-18 |
CA3037002A1 (en) | 2018-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10857182B2 (en) | Generation and use in adoptive immunotherapy of stem cell-like memory T cells | |
JP7244461B2 (ja) | 養子細胞療法のための改良型細胞培養方法 | |
Ho et al. | In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire | |
AU2017326173B2 (en) | Platform for activation and expansion of virus-specific T-cells | |
Van den Heuvel et al. | Allo-HLA cross-reactivities of cytomegalovirus-, influenza-, and varicella zoster virus–specific memory T cells are shared by different healthy individuals | |
JP2022065022A (ja) | 改変ヒト初代血液樹状細胞株を生成するための方法 | |
US6821778B1 (en) | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells | |
JP2018531022A6 (ja) | 改変ヒト初代血液樹状細胞株を生成するための方法 | |
US20130101567A1 (en) | Methods to Expand a T Regulatory Cell Master Cell Bank | |
Aspord et al. | Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases | |
Comoli et al. | Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children | |
US20200017586A1 (en) | Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy | |
JP2023512631A (ja) | Hbv特異的tcrライブラリーおよび個別化医療としてのその使用 | |
Reimann et al. | Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains | |
Ramírez et al. | Impact of T cell selection methods in the success of clinical adoptive immunotherapy | |
AU2017415310B2 (en) | Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy | |
Vivien et al. | The doubling potential of T lymphocytes allows clinical-grade production of a bank of genetically modified monoclonal T-cell populations | |
Wheatley III et al. | Dendritic cells improve the generation of Epstein-Barr virus–specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma | |
Prockop et al. | Viral Cytotoxic T Lymphocytes (CTLs): From Bench to Bedside | |
Hashmi et al. | T-Cell Therapeutics: Donor Lymphocyte Infusion, Cytotoxic T-Lymphocyte Infusion, and Other Non-CAR T-Cell Therapies | |
Schweitzer | Improving anti-viral T cell therapies by knockout of the NR4A family of transcription factors | |
Kuo et al. | T Cells Expressing Cars Directed Against HLA-0201–Rmf WT-1 Peptide Complex Can Effectively Eradicate WT1+ A0201+ Tumor Cells in-Vitro | |
Spel | Classing it up to get noticed: MHC class 1 antigen display in dendritic cells and neuroblastoma | |
Mohamed et al. | In Vitro Generated Tumor/APC Hybrids Induce Allogeneic Tumor-Killer T Cells | |
Querol et al. | Immunobiology of Cord Blood Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200918 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220418 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220418 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220426 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220526 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220527 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220617 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220621 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231019 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240119 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20240419 |